Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05998135

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma Clinical Trial

Official title:
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Clinical Trial Summary

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine progression free survival of twenty-eight patients with platinum-resistant ovarian cancer treated with atovaquone. SECONDARY OBJECTIVES: I. To determine clinical benefit rate (complete response, partial response or stable disease) at six months. II. To determine overall survival. III. To quantitate the on-target STAT3 inhibitory effect of atovaquone on STAT3-dependent gene transcription. IV. To quantitate changes of the tumor immune infiltrate by inhibition of STAT3 with atovaquone. OUTLINE: Patients receive atovaquone orally (PO) on study. Patients also undergo computed tomography (CT) and biopsy or paracentesis throughout the study. After completion of study treatment, patients are followed up for 30 days and then every 6 month thereafter. ;

Study Design

Related Conditions & MeSH terms

  • Platinum-Resistant Ovarian Carcinoma
Clinical Trial Details
NCT number NCT05998135
Study type Interventional
Source Emory University
Contact Namita Khanna, MD, MSPH
Phone 404-778-3401
Email namita.khanna@emory.edu
Status Recruiting
Phase Phase 2
Start date November 9, 2023
Completion date June 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Active, not recruiting NCT04781088 - Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Active, not recruiting NCT03587311 - Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Active, not recruiting NCT04019288 - AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 1/Phase 2
Active, not recruiting NCT03206047 - Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 1/Phase 2
Recruiting NCT05225363 - Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer Phase 1
Completed NCT02898207 - Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Phase 1
Active, not recruiting NCT01970722 - Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Phase 1
Recruiting NCT03026062 - Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase 2
Active, not recruiting NCT03691376 - Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT04753216 - Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Active, not recruiting NCT02364713 - MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Phase 2
Active, not recruiting NCT04616534 - Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Phase 1
Recruiting NCT05465941 - PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Phase 2
Not yet recruiting NCT05672095 - Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Phase 1/Phase 2
Active, not recruiting NCT02650986 - Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Phase 1/Phase 2
Recruiting NCT04055649 - ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Phase 2
Active, not recruiting NCT02020707 - Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Phase 1
Recruiting NCT05950464 - Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer Phase 1
Active, not recruiting NCT03610490 - Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Phase 2